Sun Pharma's subsidiary Taro recalled two lots of its leading blood clot drug from the market after the USFDA found that the product did not meet its quality norms.

Taro has recalled Warfarin Sodium after the USFDA faulted its poor quality. Warfarin contributes 4.5% to Taro's sales and thus just about 1% of company's sales.

Commenting on the same, Sarabjit Kour Nangra, VP Research, IT, Angel Broking, said, ''Such recalls are not new, not only to company but industry also, and since only two lots have been recalled, it would have any major impact on the company’s financials; we remain neutral on the stock.'' 

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.